Endothelin-B-receptor-selective antagonist inhibits endothelin-1 induced potentiation on the vasoconstriction to noradrenaline and angiotensin II

Journal of Hypertension

Volumn 22, Issue 10, 2004, Pages 1909-1916

  Gössl, Mario ^a   Mitchell, Anna ^a   Lerman, Amir ^b   Saez, Anabelle Opazo ^c   Schäfers, Rafael F ^a   Erbel, Raimund ^a   Philipp, Thomas ^a   Wenzel, René R ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Mayo Clinic   (United States)

^c Clinic of Internal Medicine   (Austria)

Author keywords

Angiotensin II; BQ 788 and BQ 123; Endothelin 1; Microcirculation; Noradrenaline; Potentiation; Vasoconstriction

Indexed keywords

ANGIOTENSIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NORADRENALIN;

ADULT; ARTICLE; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INJECTION; LASER DOPPLER FLOWMETRY; MICROCIRCULATION; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; SKIN BLOOD FLOW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 5044226367     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200410000-00013     Document Type: Article

References (42)

1. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999; 43:300-307.
2. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102:2434-2440.
3. Dohi Y, Lüscher TF. Endothelin in hypertensive resistance arteries. Intraluminal and extraluminal dysfunction. Hypertension 1991; 18:543-549.
4. Nucci G de, Thomas R, D'Orleans Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85:9797-9800.
5. Jougasaki M, Schirger JA, Simari RD, Burnett JC. Jr. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension 1998; 32:917-922.
6. Wenzel RR, Ruthemann J, Bruck H, Schafers RF, Michel MC, Philipp T. Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. Br J Clin Pharm 2001; 52:151-157.
7. Seo B, Oemar BS, Siebenmann R, Segesser L von, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89:1203-1208.
8. Mickley EJ, Gray GA, Webb DJ. Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharm 1997; 120:1376-1382.
9. Wang HG, Shibamoto T, Miyahara T. Endothelin-1 selectively contracts portal vein through both ETA and ETB receptors in isolated rabbit liver. Am J Physiol 1997; 273:G1036-G1043.
10. Pate MA, Chester AH, Crabbe DS, Amrani M, Brown TJ, Roach AG, Yacoub MH. Characterisation of constrictor endothelin receptors in the human internal thoracic artery and saphenous vein. J Cardiovasc Pharm 1999; 33:567-572.
11. Conant AR, Oo AY, Dashwood MR, Collard K, Chester MR, Dihmis WC, Simpson AW. Endothelin receptors in cultured and native human radial artery smooth muscle. J Cardiovasc Pharm 2002; 39:130-141.
12. Gallardo V, Cruz MA, Miguel P, Carrasco G, Gonzalez C. Mechanisms of endothelin-1-induced contraction in isolated placental veins from normal full-term and preterm pregnancies. Gen Pharm 2000; 34:295-301.
13. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999; 33:581-585.
14. Noll G, Wenzel RR, Luscher TF. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Mol Cell Biochem 1996; 157:259-267.
15. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003; 41:666-673.
16. Shepherd, AP, Öberg PA. Laser-Doppler blood flowmetry. Boston: Kluwer Academic Publishers; 1990.
17. Stern MD. In vivo evaluation of microcirculation by coherent light scattering. Nature 1975; 254:56-58.
18. Nilsson GE, Tenland T, Obert PA. A new instrument for continuous measurement of tissue blood flow by light beating spectroscopy. IEEE Trans Biomed Eng 1980; 27:12-19.
19. Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994; 23:581-586.
20. Yang ZH, Richard V, Segesser L von, Bauer E, Stulz P, Turina M, Lüscher TF. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990; 82:188-195.
21. Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Lüscher TF. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 1996; 94:316-322.
22. Seo B, Lüscher TF. ETA and ETB receptors mediate contraction to endothelin-1 in renal artery of aging SHR. Effects of FR139317 and bosentan. Hypertension 1995; 25:501-506.
23. Lodge NJ, Zhang R, Halaka NN, Moreland S. Functional role of endothelin ETA and ETB receptors in venous and arterial smooth muscle. Eur J Pharm 1995; 287:279-285.
24. Brunner F, Doherty AM. Role of ET(B) receptors in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-788. FEBS Lett 1996; 396:238-242.
25. Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M, et al. Upregulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharm 1996; 27:147-153.
26. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92:357-363.
27. Strachan FE, Crockett TR, Mills NL, Gray GA, Webb DJ. Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo. Br J Clin Pharm 2000; 50:27-30.
28. Sand AE, Ostlund E, Andersson E, Fried G. Endothelin-induced contractions in placental arteries is mediated by both ETA- and ETB-receptors. Acta Physiol Scand 1998; 163:227-234.
29. Henrion D, Laher I. Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. Hypertension 1993; 22:78-83.
30. Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera VL. Molecular characterization of a dual endothelin-1/Angiotensin II receptor. Mol Med 1998; 4:96-108.
31. Valdemarsson S, Bergdahl A, Edvinsson L. Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure. J Intern Med 1994; 235:595-601.
32. Bacon CR, Cary NR, Davenport AP. Distribution of endothelin receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharm 1995; 26(Suppl 3):S439-S441.
33. Seya K, Daitoku K, Motomura S. Norepinephrine measurement in the isolated, blood-perfused papillary muscle of the dog by using ex vivo microdialysis. J Pharm Toxicol Methods 1999; 42:149-155.
34. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001; 88:961-968.
35. Bohm F, Ahlborg G, Johansson BL, Hansson LO, Pernow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22:674-679.
36. Bruck H, Gossl M, Spitthover R, Schafers RF, Kohnle M, Philipp T, Wenzel RR. The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline- induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbine. J Hypertens 2001; 19:907-911.
37. Wenzel RR, Zbinden S, Noll G, Meier B, Lüscher TF. Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide. Br J Clin Pharm 1998; 45:441-446.
38. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98:2235-2240.
39. Schiffrin EL. State-of-the-Art lecture. Role of endothelin-1 in hypertension. Hypertension 1999; 34:876-881.
40. Sargent CA, Brazdil R, Flynn DA, Brown TJ, Roach AG. Effect of endothelin antagonists with or without BQ 788 on ET-1 responses in pithed rats. J Cardiovasc Pharm 1995; 26(Suppl 3):S216-S218.
41. Karaki H, Sudjarwo SA, Hori M. Novel antagonist of endothelin ETB1 and ETB2 receptors, BQ-788: effects on blood vessel and small intestine. Biochem Biophys Res Commun 1994; 205:168-173.
42. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91:4892-4896.